2018
136. You ZB, Bi GH, Galaj E, Kumar V, Cao J, Gadiano A, Rais R, Slusher BS, Gardner EL, Xi ZX, Newman AH. “Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects.” Neuropsychopharmacology, 2018, Nov. 27 [PubMed]
135. Barinka C, Novakova Z, Hin N, Bim D, Ferraris DV, Duvall B, Kabarrita G, Tsukamoto R, Budesinsky M, Motlova L, Rojas C, Slusher BS, Rokob TA, Rulisek L, Tsukamoto T. “Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors.” Bioorg Med Chem. 2018, Nov 14 [PubMed]
134. Rojas C, Barnaeva E, Thomas AG, Hu X, Southall N, Marugan J, Chaudhuri AD, Yoo SW, Hin N, Stepanek O, Wu Y, Zimmermann SC, Gadiano AG, Tsukamoto T, Rais R, Haughey N, Ferrer M, Slusher BS. “DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation.” Sci Rep. 2018, Dec 7;8(1):17715 [PubMed]
133. Riggle BA, Sinharay S, Schreiber-Stainthorp W, Munasinghe JP, MAric D, Prchalova E, Slusher BS, Powell JD, Miller LH, Pierce SK, Hammoud DA. “MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice.” Proc Natl Acad Sci, 2018 Dec 4 [PubMed]
132. Poore B, Yuan M, Arnold A, Price A, Alt J, Rubens JA, Slusher BS, Eberhart CG, Raabe EH. “mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.” Neuro Oncol. 2018, Sept 18 [PubMed]
131. Lemberg KM, Vornov JJ, Rais R, Slusher BS. “We’re No “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine.” Molecular Cancer Therapeutics, 2018, Sept; 17(9):1824-1832 [PubMed]
130. Chiorazzi A, Wozniak KM, Rais R, Wu Y, Gadiano A, Farah MH, Liu Y, Canta A, Alberti P, Rodriguez-Menendez V, Meregalli C, Fumagalli G, Monza L, Pozzi E, Vornov JJ, Polydefkis M, Pietra C, Slusher BS, Cavaletti G. “Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models.” European Journal of Pharmacology, 2018, Sept 27 [PubMed]
129. Kato Y, Hin N, Maita N, Thomas AG, Kurosawa S, Rojas C, Yorita K, Slusher BS, Fukui K, Tsukamoto T. “Structural basis for potent inhibition of d-amino acid oxidase by thiophene carboxylic acids.” Eur J Med Chem, 2018, Sep 18;159:23-34. [PubMed]
128. Zimmermann SC, Duvall B, Tsukamoto T. “Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase” J Med Chem. 2018 Jul 3. [PubMed]
127. Zhu X., Nedelcovych MT, Thomas AG, Hasegawa Y, Moreno-Megui A, Coomer W, Vohra V, Saito A, Perez G, Wu Y, Alt J, Prchalova E, Tenora L, Majer P, Rais R, Rojas C, Slusher BS, Kamiya A. “JHU-083 selectively blocks glutaminase activity in brain CD11b+cells and prevents depression-associated behaviors induced by chronic social defeat stress.” Neuropsychopharmacology. 2018 Aug 13. PMID 30127344 [PubMed]
126. Salvatierra J, Castro J, Erickson A, Li Q, Braz J, Gilchrist J, Grundy L, Rychkov GY, Deiteren A, Rais R, King GF, Slusher BS, Basbaum A, Pasricha PJ, Brierley SM, Bosmans F. “NaV1.1 inhibition can reduce visceral hypersensitivity.” JCI Insight. 2018 Jun 7;3(11). [PubMed]
125. Liraz-Zaltsman S, Slusher BS, Atrakchi-Baranes D, Rosenblatt K, Friedman Levi Y, Kesner EL, Silva AJ, Biegon A, Shohami E. “Enhancement of brain D-serine mediates recovery of cognitive function after TBI.” J Neurotrauma, 2018 July 15; 35:1667-1680 [PubMed]
124. Zimmermann SC, Tichy T, Vavra J, Dash RP, Slusher CE, Gadiano AJ, Wu Y, Jancarik A, Tenora L, Monincova L, Prchalova E, Riggins GJ, Majer P, Slusher BS, Rais R. “N-Substituted Prodrugs of Mebendazole Provide Improved Aqueous Solubility and Oral Bioavailability in Mice and Dogs.” J Med Chem. 2018 May 10;61(9): 3918-3929 [PubMed]
123. Tunstall BJ, Ho CP, Cao J, Vendruscolo JCM, Schmeichel BE, Slack RD, Tanda G, Gadiano AJ, Rais R, Slusher BS, Koob GF, Newman AH, Vendruscolo LF. “Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats.” Neuropharmacology, 2018, Mar 15, 131:96-103. [PubMed]
122. Wozniak KM, Vornov JJ, Wu Y, Liu Y, Carozzi VA, Rodriguez-Menendez V, Ballarini E, Alberti P, Pozzi E, Semperboni S, Cook BM, Littlefield BA, Nomoto K, Condon K, Eckley S, DesJardins C, Wilson L, Jordan MA, Feinstein SC, Cavaletti G, Polydefkis M, Slusher BS. “Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery.” Cancer Res. 2018, Feb 1;78(3):817-829 [PubMed]
121. Soomro I, Sun Y, Li Z, Diggs L, Hatzivassiliou G, Thomas AG, Rais R, Slusher BS, Somlo S, Skolnik EY. “Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.” Nephrol Dial Transplant. 2018 Aug;Vol 33, Issue 8:1343-1353 [PubMed]
120. Nedelcovych MT, Gadiano AJ, Wu Y, Manning AA, Thomas AG, Khuder SS, Yoo SW, Xu J, McArthur JC, Haughey NJ, Volsky DJ, Rais R, Slusher BS. “Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse.” ACS Chem Neurosci. 2018 Apr 18;9(4):809-816 [PubMed]
119. Rojas C, Stathis M, Coughlin JM, Pomper M, Slusher BS. “The Low-Affinity Binding of Second Generation Radiotracers Targeting TSPO is Associated with a Unique Allosteric Binding Site.” J Neuroimmune Pharmacol. 2018 Mar;13(1):1-5 [PubMed]
118. Dash RP, Rais R, Srinivas NR. “Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition.” Xenobiotica, 2018, May 48(5):442-451 [PubMed]
117. Dash RP, Rais R. Srinivas NR. “Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview.” Xenobiotica. 2018, Apr 48(4):422-432 [PubMed]